Your browser doesn't support javascript.
loading
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Gomez-Roca, C A; Italiano, A; Le Tourneau, C; Cassier, P A; Toulmonde, M; D'Angelo, S P; Campone, M; Weber, K L; Loirat, D; Cannarile, M A; Jegg, A-M; Ries, C; Christen, R; Meneses-Lorente, G; Jacob, W; Klaman, I; Ooi, C-H; Watson, C; Wonde, K; Reis, B; Michielin, F; Rüttinger, D; Delord, J-P; Blay, J-Y.
Affiliation
  • Gomez-Roca CA; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse. Electronic address: gomez-roca.carlos@iuct-oncopole.fr.
  • Italiano A; Department of Medical Oncology, Institut Bergonié, Bordeaux. Electronic address: a.italiano@bordeaux.unicancer.fr.
  • Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud; INSERM U900 Research Unit, Saint-Cloud; Paris-Saclay University, Paris.
  • Cassier PA; Department of Medicine, Centre Léon Bérard, Lyon, France.
  • Toulmonde M; Department of Medical Oncology, Institut Bergonié, Bordeaux.
  • D'Angelo SP; Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, USA.
  • Campone M; ICO René Gauducheau, Saint-Herblain, France.
  • Weber KL; Department of Orthopedic Oncology, Penn Medicine, Pennsylvania, USA.
  • Loirat D; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud.
  • Cannarile MA; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Jegg AM; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Ries C; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Christen R; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.
  • Meneses-Lorente G; Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn Garden City.
  • Jacob W; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Klaman I; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Ooi CH; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.
  • Watson C; A4P Consulting Ltd, Sandwich, UK.
  • Wonde K; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.
  • Reis B; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.
  • Michielin F; Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland.
  • Rüttinger D; Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany.
  • Delord JP; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud.
  • Blay JY; Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
Ann Oncol ; 30(8): 1381-1392, 2019 08 01.
Article de En | MEDLINE | ID: mdl-31114846
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Paclitaxel / Anticorps monoclonaux humanisés / Macrophages / Tumeurs Type d'étude: Clinical_trials / Prognostic_studies Limites: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2019 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Paclitaxel / Anticorps monoclonaux humanisés / Macrophages / Tumeurs Type d'étude: Clinical_trials / Prognostic_studies Limites: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2019 Type de document: Article